Drug intelligence / Profile preview

WD-940

Development stage: Preclinical
Lead developer: Zhejiang Wenda Pharmaceutical Technology
Modality: Small Molecules

Overview

WD-940 is a preclinical small-molecule inhibitor developed by Ningbo Wenda Pharmaceutical Technology. It specifically targets Human Epidermal Growth Factor Receptor 2 (HER2), with a focus on activity against HER2 exon 20 insertion mutations. These mutations are common drivers in certain types of non-small cell lung cancer (NSCLC) and other solid tumors, often conferring resistance to standard HER2-targeted therapies. WD-940 is being developed for the treatment of HER2-mutant tumors, particularly those harboring the exon 20 insertion.

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on WD-940.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WD-940.

Explore the full profile